GTHX - G1 Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
867.01M
Enterprise Value 3
567.62M
Trailing P/E
N/A
Forward P/E 1
-6.27
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
3.03
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-4.80

Trading Information

Stock Price History

Beta (3Y Monthly) 2.15
52-Week Change 3-25.54%
S&P500 52-Week Change 318.18%
52 Week High 341.80
52 Week Low 313.87
50-Day Moving Average 322.35
200-Day Moving Average 326.60

Share Statistics

Avg Vol (3 month) 3404.2k
Avg Vol (10 day) 3391.66k
Shares Outstanding 537.58M
Float 27.91M
% Held by Insiders 117.81%
% Held by Institutions 189.86%
Shares Short (Nov 15, 2019) 45.25M
Short Ratio (Nov 15, 2019) 419.43
Short % of Float (Nov 15, 2019) 421.69%
Short % of Shares Outstanding (Nov 15, 2019) 413.96%
Shares Short (prior month Oct 15, 2019) 44.76M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-20.87%
Return on Equity (ttm)-33.39%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-70.68M
EBITDA -118.3M
Net Income Avi to Common (ttm)-111.1M
Diluted EPS (ttm)-2.97
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)299.93M
Total Cash Per Share (mrq)7.98
Total Debt (mrq)10.32M
Total Debt/Equity (mrq)3.61
Current Ratio (mrq)14.28
Book Value Per Share (mrq)7.61

Cash Flow Statement

Operating Cash Flow (ttm)-90.79M
Levered Free Cash Flow (ttm)-54.8M